Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Other Operating Expenses (2020 - 2025)

Cytek Biosciences' Other Operating Expenses history spans 6 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 10.59% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $49.4 million, up 0.66%, while the annual FY2025 figure was $49.4 million, 0.66% up from the prior year.
  • Other Operating Expenses reached $13.1 million in Q4 2025 per CTKB's latest filing, up from $11.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $13.1 million in Q4 2025 to a low of -$6.2 million in Q1 2023.
  • Average Other Operating Expenses over 5 years is $7.5 million, with a median of $10.3 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: crashed 226.69% in 2023, then skyrocketed 375.31% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $8.3 million in 2021, then rose by 8.73% to $9.0 million in 2022, then grew by 28.04% to $11.6 million in 2023, then grew by 2.71% to $11.9 million in 2024, then rose by 10.59% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Other Operating Expenses are $13.1 million (Q4 2025), $11.7 million (Q3 2025), and $12.1 million (Q2 2025).